Biovail’s Ralivia receives approvable letter
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.
FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.
The $300,000 grant will go towards an abuse-deterrent technology.
A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.